← Leaderboards
David John Tweardy
Baylor College Of Medicine
$14,168,425
Attributed
$16,557,596
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,557,596 · 14
By mechanism
R01$8,037,412 · 5
P50$4,162,379 · 4
R42$1,714,825 · 1
T32$1,501,662 · 1
R21$724,923 · 2
R41$416,395 · 1
Top collaborators
- Andrew Sikora4 shared
- Faye Johnson3 shared
- Seyed Javad Mirhassani Moghaddam2 shared
- Ferdinandos Skoulidis2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Powel H Brown$10,794,797
- Stacey L Berg$977,573
- Jenny C-N Chang$6,753,372
- Xiangwei Wu$7,480,443
- Thomas Alexander Cooper$24,564,195
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorSmall MoleculeLeadCellsOralPreventDockingTumor GrowthSafetyGrowthMouse ModelMalignant NeoplasmsStat3 GenePhase 1 StudyNeoplastic CellComputersToxic EffectInhibitor/AntagonistProteinsCancer CenterClinical TrialsStat3 ProteinSignal TransductionDose
Grant awards (50)
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$671,795
R01 · FY2025 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$666,718
R01 · FY2025 · CA · contact PI
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$672,297
R01 · FY2024 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$410,323
R01 · FY2024 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$657,573
R01 · FY2023 · CA · contact PI
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease$432,645
P50 · FY2023 · CA · contact PI
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC$376,648
P50 · FY2023 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$671,730
R01 · FY2022 · CA · contact PI
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease$437,204
P50 · FY2022 · CA · contact PI
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC$376,649
P50 · FY2022 · CA · contact PI
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC$556,316
P50 · FY2021 · CA · contact PI
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease$248,429
P50 · FY2021 · CA · contact PI
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease$490,198
P50 · FY2020 · CA · contact PI
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC$387,763
P50 · FY2020 · CA · contact PI
Project 2: Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease$479,877
P50 · FY2019 · CA · contact PI
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC$376,650
P50 · FY2019 · CA · contact PI
Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease$1,330,109
R42 · FY2017 · DK · contact PI
Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease$169,159
R42 · FY2017 · DK · contact PI
Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease$215,557
R42 · FY2016 · DK · contact PI
Targeting Stat1 and Stat3 to Reverse Radioresistance in Head and Neck Cancer$156,600
R21 · FY2016 · CA · contact PI
Targeting Stat1 and Stat3 to Reverse Radioresistance in Head and Neck Cancer$206,081
R21 · FY2015 · CA · contact PI
Research Training in Infection and Immunity$170,520
T32 · FY2014 · AI · contact PI
Chemical probes that target Stat3 to treat cancer$139,030
R41 · FY2013 · CA · contact PI
Chemical probes that target Stat3 to treat cancer$277,365
R41 · FY2012 · CA · contact PI
Research Training in Infections and Immunity$180,062
T32 · FY2012 · AI · contact PI
Stat3 Probes that Target Breast Cancer Stem Cells$161,924
R21 · FY2011 · CA · contact PI
Research Training in Infections and Immunity$135,466
T32 · FY2011 · AI · contact PI
Stat3 Probes that Target Breast Cancer Stem Cells$200,318
R21 · FY2010 · CA · contact PI
Research Training in Infections and Immunity$134,074
T32 · FY2010 · AI · contact PI
Research Training in Infections and Immunity$133,024
T32 · FY2009 · AI · contact PI
Research Training in Infections and Immunity$131,988
T32 · FY2008 · AI · contact PI
REVERSAL OF HYPOVOLEMIC CIRCULATORY COLLAPSE BY IL-6$356,753
R01 · FY2007 · HL · contact PI
Research Training in Infections and Immunity$122,047
T32 · FY2007 · AI · contact PI
REVERSAL OF HYPOVOLEMIC CIRCULATORY COLLAPSE BY IL-6$367,408
R01 · FY2006 · HL · contact PI
Mechanisms of G-CSF Receptor Mediated Differentiation$276,291
R01 · FY2006 · CA · contact PI
Research Training in Infections and Immunity$125,980
T32 · FY2006 · AI · contact PI
REVERSAL OF HYPOVOLEMIC CIRCULATORY COLLAPSE BY IL-6$376,250
R01 · FY2005 · HL
Mechanisms of G-CSF Receptor Mediated Differentiation$282,940
R01 · FY2005 · CA
Research Training in Infections and Immunity$121,880
T32 · FY2005 · AI
REVERSAL OF HYPOVOLEMIC CIRCULATORY COLLAPSE BY IL-6$376,250
R01 · FY2004 · HL
Mechanisms of G-CSF Receptor Mediated Differentiation$282,940
R01 · FY2004 · CA
Research Training in Infections and Immunity$126,168
T32 · FY2004 · AI
STAT3 INTERACTIONS IN CELL GROWTH AND DIFFERENTIATION$299,019
R01 · FY2003 · CA
Mechanisms of G-CSF Receptor Mediated Differentiation$282,940
R01 · FY2003 · CA
Research Training in Infections and Immunity$120,453
T32 · FY2003 · AI
STAT3 INTERACTIONS IN CELL GROWTH AND DIFFERENTIATION$291,547
R01 · FY2002 · CA
Mechanisms of G-CSF Receptor Mediated Differentiation$282,940
R01 · FY2002 · CA
STAT3 INTERACTIONS IN CELL GROWTH AND DIFFERENTIATION$284,293
R01 · FY2001 · CA
STAT3 INTERACTIONS IN CELL GROWTH AND DIFFERENTIATION$277,530
R01 · FY2000 · CA
MECHANISMS OF G-CSF RECEPTOR MEDIATED DIFFERENTIATION$249,875
R01 · FY2000 · CA